Abstracts concerning indolent and aggressive lymphoma and multiple myeloma with clinical relevance from the ASCO 2017 meeting are discussed.
Rummel, MJ, et al. Bendamustine Plus Rituximab (B-R) versus CHOP Plus Rituximab (CHOP-R) as first-line treatment in patients with indolent and mantle cell lymphomas (MCL) – 7 Year Updated Results from the StiL NHL1 Study. Blood. 2014;124:4407.